Risk of HBV reactivation in relapsed or refractory diffuse large B-cell lymphoma patients receiving Bruton tyrosine kinase inhibitors therapy

BACKGROUND: Bruton tyrosine kinase inhibitors (BTKis) interrupt B-cell receptor signaling and thereby could potentially reactivate hepatitis B virus (HBV). However, data about the risk for HBV reactivation (HBVr) of BTKis in relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) patients a...

Descripción completa

Detalles Bibliográficos
Autores principales: Ni, Ying, Gao, Lixia, Lu, Yan, Ye, Shiguang, Zhou, Lili, Qian, Wenbin, Liang, Aibin, Li, Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9471857/
https://www.ncbi.nlm.nih.gov/pubmed/36119029
http://dx.doi.org/10.3389/fimmu.2022.982346

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9471857/
https://www.ncbi.nlm.nih.gov/pubmed/36119029
http://dx.doi.org/10.3389/fimmu.2022.982346

Ejemplares similares